Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial

Agnihotram V Ramanakumar, Paulo Naud, Cecilia M Roteli-Martins, Newton S de Carvalho, Paola C de Borba, Julio C Teixeira, Mark Blatter, Anna-Barbara Moscicki, Diane M Harper, Barbara Romanowski, Stephen K Tyring, Brian Ramjattan, Anne Schuind, Gary Dubin, Eduardo L Franco, HPV-007 Study Group, Agnihotram V Ramanakumar, Paulo Naud, Cecilia M Roteli-Martins, Newton S de Carvalho, Paola C de Borba, Julio C Teixeira, Mark Blatter, Anna-Barbara Moscicki, Diane M Harper, Barbara Romanowski, Stephen K Tyring, Brian Ramjattan, Anne Schuind, Gary Dubin, Eduardo L Franco, HPV-007 Study Group

Abstract

Objectives: Persistence of human papillomaviruses (HPVs) is necessary for cervical carcinogenesis. We evaluated incidence and duration of type-specific HPV infections and the influence of age and number of sexual partners.

Methods: Data were obtained from 553 women (15-25 years), who were seronegative and DNA-negative for high-risk HPV (HR-HPV) types and were enrolled in the placebo arm of a randomised trial of the HPV-16/18 vaccine (NCT00689741/NCT00120848). They were followed for 6.3 years. Cervicovaginal samples were self-collected at 3-month intervals for up to 27 months, and cervical samples were collected by clinicians at 6-month intervals until study end. Samples were tested for HPV types using a broad-spectrum PCR assay. Incidence rate ratios (RRs) and 95% CIs were used to estimate the association among age, sexual habits and HPV acquisition.

Results: Incidence rates (95% CI) using cervical samples were 11.8 (10.4 to 13.4) and 5.6 (4.7 to 6.6) per 1000 women-months for HR-HPVs and low-risk HPVs (LR-HPVs), respectively. Equivalent rates in combined cervicovaginal and cervical samples were 17.2 (15.4 to 19.2) and 6.9 (5.9 to 8.0), respectively. 54 per cent of HR-HPV types from combined cervicovaginal and cervical samples persisted for 1 year compared with 32.3% for LR-HPV types. The risk of acquiring any HPV infection was higher among women aged <21 years (RR=1.33, 95% CI 1.1 to 1.7) and women having >1 sexual partner (RR=1.83, 95% CI 1.4 to 2.4) at baseline.

Conclusions: HR-HPV infections were more common and lasted longer on average than LR-HPV infections. HPV acquisition was more common in younger women with multiple sexual partners.

Trial registration number: NCT00689741, NCT00120848; Post-results.

Keywords: Cervical cancer; Cohort study; EPIDEMIOLOGY; Human papillomavirus; Natural history.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Cumulative probability of persistent detection of the first episode of HPV infection (as per liberal definition) over time stratified by age (upper graphs A, B, C; solid line

Figure 2

Cumulative probability of detecting an…

Figure 2

Cumulative probability of detecting an HPV infection over time stratified by the age…

Figure 2
Cumulative probability of detecting an HPV infection over time stratified by the age group (upper graphs A, B, C; solid line
Similar articles
References
    1. Walboomers JM, Jacobs MV, Manos MM et al. . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F - DOI - PubMed
    1. Bosch FX, Burchell AN, Schiffman M et al. . Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1–16. - PubMed
    1. Moscicki AB, Widdice L, Ma Y et al. . Comparison of natural histories of human papillomavirus detected by clinician- and self-sampling. Int J Cancer 2010;127:1882–92. 10.1002/ijc.25199 - DOI - PMC - PubMed
    1. Sundstrom K, Eloranta S, Sparen P et al. . Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev 2010;19:2469–78. 10.1158/1055-9965.EPI-10-0424 - DOI - PMC - PubMed
    1. Castle PE, Rodriguez AC, Burk RD et al. . Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis 2011;203:814–22. 10.1093/infdis/jiq116 - DOI - PMC - PubMed
Show all 38 references
Publication types
MeSH terms
Associated data
Related information
LinkOut - more resources
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 2
Figure 2
Cumulative probability of detecting an HPV infection over time stratified by the age group (upper graphs A, B, C; solid line

References

    1. Walboomers JM, Jacobs MV, Manos MM et al. . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>;2-F
    1. Bosch FX, Burchell AN, Schiffman M et al. . Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1–16.
    1. Moscicki AB, Widdice L, Ma Y et al. . Comparison of natural histories of human papillomavirus detected by clinician- and self-sampling. Int J Cancer 2010;127:1882–92. 10.1002/ijc.25199
    1. Sundstrom K, Eloranta S, Sparen P et al. . Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev 2010;19:2469–78. 10.1158/1055-9965.EPI-10-0424
    1. Castle PE, Rodriguez AC, Burk RD et al. . Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis 2011;203:814–22. 10.1093/infdis/jiq116
    1. Schlecht NF, Kulaga S, Robitaille J et al. . Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106–14. 10.1001/jama.286.24.3106
    1. Richardson H, Abrahamowicz M, Tellier PP et al. . Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005;14:1149–56. 10.1158/1055-9965.EPI-04-0230
    1. Liaw KL, Glass AG, Manos MM et al. . Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954–60. 10.1093/jnci/91.11.954
    1. Kjaer SK, van den Brule AJ, Paull G et al. . Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572 10.1136/bmj.325.7364.572
    1. Kjaer SK, Frederiksen K, Munk C et al. . Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478–88. 10.1093/jnci/djq356
    1. Bosch FX, Manos MM, Munoz N et al. . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796–802.
    1. Munoz N, Bosch FX, de Sanjose S et al. . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–27. 10.1056/NEJMoa021641
    1. Parada R, Morales R, Giuliano AR et al. . Prevalence, concordance and determinants of human papillomavirus infection among heterosexual partners in a rural region in central Mexico. BMC Infect Dis 2010;10:223 10.1186/1471-2334-10-223
    1. Richardson H, Franco E, Pintos J et al. . Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex Transm Dis 2000;27:79–86. 10.1097/00007435-200002000-00005
    1. Trottier H, Mahmud S, Prado JC et al. . Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008;197:1436–47. 10.1086/587698
    1. Ho GY, Bierman R, Beardsley L et al. . Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–8. 10.1056/NEJM199802123380703
    1. Kotloff KL, Wasserman SS, Russ K et al. . Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 1998;25:243–50. 10.1097/00007435-199805000-00005
    1. Richardson H, Kelsall G, Tellier P et al. . The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485–90.
    1. Brown DR, Shew ML, Qadadri B et al. . A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182–92. 10.1086/426867
    1. Koshiol JE, Schroeder JC, Jamieson DJ et al. . Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006;119:1623–9. 10.1002/ijc.22015
    1. Molano M, Van den Brule A, Plummer M et al. . Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486–94. 10.1093/aje/kwg171
    1. Syrjanen S, Shabalova I, Petrovichev N et al. . Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union. Int J STD AIDS 2005;16:217–23. 10.1258/0956462053420211
    1. Insinga RP, Dasbach EJ, Elbasha EH et al. . Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709–15. 10.1158/1055-9965.EPI-06-0846
    1. Harper DM, Franco EL, Wheeler C et al. . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757–65. 10.1016/S0140-6736(04)17398-4
    1. Harper DM, Franco EL, Wheeler CM et al. . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247–55. 10.1016/S0140-6736(06)68439-0
    1. Trottier H, Mahmud SM, Lindsay L et al. . Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev 2009;18:854–62. 10.1158/1055-9965.EPI-08-1012
    1. Schmeink CE, Massuger LF, Lenselink CH et al. . Prospective follow-up of 2,065 young unscreened women to study human papillomavirus incidence and clearance. Int J Cancer 2013;133:172–81. 10.1002/ijc.27986
    1. Winer RL, Hughes JP, Feng Q et al. . Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J Infect Dis 2009;199:815–18.
    1. Franco EL, Villa LL, Sobrinho JP et al. . Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415–23. 10.1086/315086
    1. Mori S, Nakao S, Kukimoto I et al. . Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci 2011;102:1223–7. 10.1111/j.1349-7006.2011.01922.x
    1. Kleter B, van Doorn LJ, Schrauwen L et al. . Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508–17.
    1. Woodman CB, Collins S, Winter H et al. . Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831–6. 10.1016/S0140-6736(00)04956-4
    1. Moscicki AB, Shiboski S, Broering J et al. . The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132: 277–84. 10.1016/S0022-3476(98)70445-7
    1. Bosch FX, Lorincz A, Munoz N et al. . The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–65. 10.1136/jcp.55.4.244
    1. Fakhry C, Sugar E, D'Souza G et al. . Two-week versus six-month sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort. PLoS One 2010;5:e11918 10.1371/journal.pone.0011918
    1. Moscicki AB, Palefsky J, Smith G et al. . Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet Gynecol 1993;82:578–85.
    1. Hildesheim A, Schiffman MH, Gravitt PE et al. . Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235–40. 10.1093/infdis/169.2.235
    1. Smelov V, Eklund C, Arroyo Mühr LS et al. . Are human papillomavirus DNA prevalences providing high-flying estimates of infection? An international survey of HPV detection on environmental surfaces. Sex Transm Infect 2013;89:627 10.1136/sextrans-2013-051280

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir